Courier Capital LLC Has $11.01 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Courier Capital LLC lessened its position in Johnson & Johnson (NYSE:JNJ) by 1.8% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 69,617 shares of the company’s stock after selling 1,275 shares during the quarter. Courier Capital LLC’s holdings in Johnson & Johnson were worth $11,013,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Gallagher Fiduciary Advisors LLC increased its holdings in shares of Johnson & Johnson by 18.9% during the 3rd quarter. Gallagher Fiduciary Advisors LLC now owns 2,577 shares of the company’s stock worth $401,000 after acquiring an additional 409 shares during the last quarter. New England Asset Management Inc. increased its holdings in shares of Johnson & Johnson by 11.3% during the 3rd quarter. New England Asset Management Inc. now owns 46,936 shares of the company’s stock worth $7,310,000 after acquiring an additional 4,750 shares during the last quarter. Gateway Advisory LLC increased its holdings in shares of Johnson & Johnson by 179.4% during the 3rd quarter. Gateway Advisory LLC now owns 17,794 shares of the company’s stock worth $2,771,000 after acquiring an additional 11,425 shares during the last quarter. Wahed Invest LLC increased its holdings in shares of Johnson & Johnson by 2.2% during the 3rd quarter. Wahed Invest LLC now owns 38,183 shares of the company’s stock worth $5,947,000 after acquiring an additional 805 shares during the last quarter. Finally, Axxcess Wealth Management LLC increased its holdings in shares of Johnson & Johnson by 71.8% during the 3rd quarter. Axxcess Wealth Management LLC now owns 66,481 shares of the company’s stock worth $10,354,000 after acquiring an additional 27,795 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $146.16 on Friday. The stock has a fifty day moving average price of $148.14 and a 200-day moving average price of $154.07. The company has a market cap of $351.76 billion, a price-to-earnings ratio of 9.11, a PEG ratio of 2.43 and a beta of 0.53. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.94 and a current ratio of 1.17. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $175.97.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, topping the consensus estimate of $2.64 by $0.07. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. The business had revenue of $21.38 billion during the quarter, compared to the consensus estimate of $21.39 billion. During the same period in the prior year, the company earned $2.68 EPS. Johnson & Johnson’s revenue for the quarter was up 2.3% on a year-over-year basis. As a group, equities analysts anticipate that Johnson & Johnson will post 10.62 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st were given a dividend of $1.24 per share. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.19. This represents a $4.96 annualized dividend and a dividend yield of 3.39%. The ex-dividend date of this dividend was Monday, May 20th. Johnson & Johnson’s dividend payout ratio is currently 30.92%.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the company. Morgan Stanley decreased their target price on Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating on the stock in a report on Wednesday, April 17th. HSBC upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and boosted their price target for the company from $169.00 to $170.00 in a research note on Thursday, April 18th. Royal Bank of Canada restated an “outperform” rating and issued a $175.00 price target on shares of Johnson & Johnson in a research note on Monday, June 17th. Bank of America reduced their price target on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a research note on Wednesday, April 17th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a research note on Thursday, June 20th. Eight equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $174.07.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.